Takara Bio Inc. (FRA:TF2)

Market Cap	537.00M
Revenue (ttm)	253.84M
Net Income (ttm)	-36.76M
Shares Out	n/a
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	0.10 (2.61%)
Ex-Dividend Date	Mar 28, 2025

Volume	514
Average Volume	109
Open	4.100
Previous Close	4.080
Day's Range	4.000 - 4.100
52-Week Range	3.840 - 6.450
Beta	n/a
RSI	50.99
Earnings Date	Feb 13, 2026

About Takara Bio

Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for COVID-19 testing. It also provides contract services related to regenerative medicine products and contract services related to gene analysis and test...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 1,779
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TF2

Financial Performance

In 2024, Takara Bio's revenue was 45.04 billion, an increase of 3.53% compared to the previous year's 43.51 billion. Earnings were 1.04 billion, a decrease of -29.66%.

Financial numbers in JPY